LOR has been approved as a first-line treatment for untreated EML4-ALK-positive NSCLC patients and as a second-line treatment for previously ALK-inhibitor-treated EML4-ALK-positive NSCLC patients [14, 15]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.